Phase II trial of oral vinorelbine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) positive mutation after a failure to treatment with EGFR Tyrosine Kinase Inhibitors (TKI) in first line.

Trial Profile

Phase II trial of oral vinorelbine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) positive mutation after a failure to treatment with EGFR Tyrosine Kinase Inhibitors (TKI) in first line.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Vinorelbine (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms NAVoTRIAL 2
  • Sponsors Pierre Fabre
  • Most Recent Events

    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
    • 28 Jul 2016 New trial record
    • 07 Jun 2016 Results (n=30) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top